Global Information
회사소개 | 문의
SALE

파브리병 : 주요 21개국 시장 예측

EPIOMIC EPIDEMIOLOGY SERIES: FABRY DISEASE FORECAST IN 21 MAJOR MARKETS 2018-2028

리서치사 Black Swan Analysis
발행일 2018년 07월 상품 코드 344276
페이지 정보 영문 74 Pages
가격
US $ 5,800 US $ 5,104 ₩ 5,820,000 PDF by E-mail (Single User License)
US $ 8,700 US $ 7,656 ₩ 8,730,000 PDF by E-mail (Site License)
US $ 10,400 US $ 9,152 ₩ 10,436,000 PDF by E-mail (Global License)


파브리병 : 주요 21개국 시장 예측 EPIOMIC EPIDEMIOLOGY SERIES: FABRY DISEASE FORECAST IN 21 MAJOR MARKETS 2018-2028
발행일 : 2018년 07월 페이지 정보 : 영문 74 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

주요 21개 시장(미국, 캐나다, 프랑스, 독일, 이탈리아, 스페인, 영국, 폴란드, 네덜란드, 오스트리아, 포르투갈, 러시아, 터키, 일본, 중국, 한국, 인도, 호주, 브라질, 멕시코, 아르헨티나)의 파브리병(FABRY DISEASE) 현재 환자수(성별, 연령 그룹별)에 대해 조사 분석했으며, 현재 유병률, 질환 개요, 위험인자, 질환 진단과 예후, 주요 증상과 합병증 등의 정보를 정리하여 전해드립니다.

1. 도표

2. 서론

3. 병인

4. 위험인자와 예방

5. 질환 진단

6. 변이 : 지역/민족별

7. 질환의 예후와 임상 경과

8. 질환에 관련된 주요 합병증/특징

9. 환자수 정량화 방법

10. 파브리병 최대 환자수

11. 파브리병 환자의 특징

  • 파브리병의 증상
  • 파브리병 환자의 병존질환

12. 약어

13. 기타 서비스 솔루션

  • 보고서 및 출판물
  • 온라인 역학 데이터베이스
  • 온라인 약가 데이터베이스

14. 참고 문헌

15. 부록

LSH 18.07.12

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Fabry Disease in 21 Major Markets

Fabry disease is a lysosomal storage disorder, caused by a genetic defect in the alpha-galactosidase-A gene (αGLA-gene), localized on the long arm of the X-chromosome (Xq22). This gene is essential in the breakdown of fatty substances, otherwise substances like globotriaosylceramide, will accumulate in the arteries, narrowing them and reducing blood flow around the body. It is a multi-system disorder characterised by dermatologic angiokeratoma corporis diffusum and purpura haemorrhagica nodularis, but also affects ocular, auditory, cardiac, digestive and renal systems.

This report provides the current prevalent population for Fabry Disease across 21 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Austria, Portugal, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Fabry disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Fabry disease include:

Angiokeratoma

Cornea verticillata (corneal whorling)

Hearing loss

Tinnitus

Proteinuria

Cardiac hypertrophy & arrhythmias

Sweating dysfunction

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

Able to quantify patient populations in global Fabry disease market to target the development of future products, pricing strategies and launch plans.

Gain further insight into the prevalence of the subdivided types of Fabry disease and identify patient segments with high potential.

Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.

Provide a level of understanding on the impact from specific co-morbid conditions on Fabry disease prevalent population.

Identify sub-populations within Fabry disease which require treatment.

Gain an understanding of the specific markets that have the largest number of Fabry disease patients.

CONTENTS

  • LIST OF TABLES AND FIGURES
  • INTRODUCTION
  • CAUSE OF THE DISEASE
  • RISK FACTORS & PREVENTION
  • DIAGNOSIS OF THE DISEASE
  • VARIATION BY GEOGRAPHY/ETHNICITY
  • DISEASE PROGNOSIS & CLINICAL COURSE
  • KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE
  • METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS
  • TOP-LINE PREVALENCE FOR FABRY DISEASE
  • FEATURES OF FABRY DISEASE PATIENTS
  • FABRY DISEASE SYMPTOM GROUPS
  • COMORBIDITIES OF FABRY DISEASE PATIENTS
  • ABBREVIATIONS USED IN THE REPORT
  • OTHER BLACK SWAN SERVICES & SOLUTIONS
  • REPORTS & PUBLICATIONS
  • ONLINE EPIDEMIOLOGY DATABASES
  • ONLINE PHARMACEUTICAL PRICING DATABASE
  • REFERENCES
  • APPENDIX

LIST OF TABLES AND FIGURES

  • Table 1. Questions to help diagnosis of Hearing Loss
  • Table 2. Prevalence of Fabry disease, total (000s)
  • Table 3. Prevalence of Fabry disease, males (000s)
  • Table 4. Prevalence of Fabry disease, females (000s)
  • Table 5. Fabry disease patients with auditory involvement by severity of hearing loss, total (000s)
  • Table 6. Fabry disease patients with auditory involvement by severity of hearing loss, total (000s)
  • Table 7. Fabry disease patients with urinary/renal involvement by type of impairment, total (000s)
  • Table 8. Fabry disease patients with neurological symptoms / pain, total (000s)
  • Table 9. Fabry disease patients with dermatological symptoms, total (000s)
  • Table 10. Fabry disease patients with cardiac symptoms, total (000s)
  • Table 11. Fabry disease patients with cerebrovascular symptoms, total (000s)
  • Table 12. Fabry disease patients with gastrointestinal symptoms, total (000s)
  • Table 13. Fabry disease patients with renal/urinary symptoms, total (000s)
  • Table 14. Fabry disease patients with auditory symptoms, total (000s)
  • Table 15. Fabry disease patients with ocular symptoms, total (000s)
  • Table 16. Fabry disease patients with vascular symptoms, total (000s)
  • Table 17. Fabry disease patients with right ventricular hypertrophy, total (000s)
  • Table 18. Abbreviations and acronyms used in the report
  • Table 19. USA prevalence of Fabry disease by 5-yr age cohort, males (000s)
  • Table 20. USA prevalence of Fabry disease by 5-yr age cohort, females (000s)
  • Table 21. Canada prevalence of Fabry disease by 5-yr age cohort, males (000s)
  • Table 22. Canada prevalence of Fabry disease by 5-yr age cohort, females (000s)
  • Table 23. France prevalence of Fabry disease by 5-yr age cohort, males (000s)
  • Table 24. France prevalence of Fabry disease by 5-yr age cohort, females (000s)
  • Table 25. Germany prevalence of Fabry disease by 5-yr age cohort, males (000s)
  • Table 26. Germany prevalence of Fabry disease by 5-yr age cohort, females (000s)
  • Table 27. Italy prevalence of Fabry disease by 5-yr age cohort, males (000s)
  • Table 28. Italy prevalence of Fabry disease by 5-yr age cohort, females (000s)
  • Table 29. Spain prevalence of Fabry disease by 5-yr age cohort, males (000s)
  • Table 30. Spain prevalence of Fabry disease by 5-yr age cohort, females (000s)
  • Table 31. UK prevalence of Fabry disease by 5-yr age cohort, males (000s)
  • Table 32. UK prevalence of Fabry disease by 5-yr age cohort, females (000s)
  • Table 33. Poland prevalence of Fabry disease by 5-yr age cohort, males (000s)
  • Table 34. Poland prevalence of Fabry disease by 5-yr age cohort, females (000s)
  • Table 35. Netherlands prevalence of Fabry disease by 5-yr age cohort, males (000s)
  • Table 36. Netherlands prevalence of Fabry disease by 5-yr age cohort, females (000s)
  • Table 37. Austria prevalence of Fabry disease by 5-yr age cohort, males (000s)
  • Table 38. Austria prevalence of Fabry disease by 5-yr age cohort, females (000s)
  • Table 39. Portugal prevalence of Fabry disease by 5-yr age cohort, males (000s)
  • Table 40. Portugal prevalence of Fabry disease by 5-yr age cohort, females (000s)
  • Table 41. Russia prevalence of Fabry disease by 5-yr age cohort, males (000s)
  • Table 42. Russia prevalence of Fabry disease by 5-yr age cohort, females (000s)
  • Table 43. Turkey prevalence of Fabry disease by 5-yr age cohort, males (000s)
  • Table 44. Turkey prevalence of Fabry disease by 5-yr age cohort, females (000s)
  • Table 45. Japan prevalence of Fabry disease by 5-yr age cohort, males (000s)
  • Table 46. Japan prevalence of Fabry disease by 5-yr age cohort, females (000s)
  • Table 47. China prevalence of Fabry disease by 5-yr age cohort, males (000s)
  • Table 48. China prevalence of Fabry disease by 5-yr age cohort, females (000s)
  • Table 49. South Korea prevalence of Fabry disease by 5-yr age cohort, males (000s)
  • Table 50. South Korea prevalence of Fabry disease by 5-yr age cohort, females (000s)
  • Table 51. India prevalence of Fabry disease by 5-yr age cohort, males (000s)
  • Table 52. India prevalence of Fabry disease by 5-yr age cohort, females (000s)
  • Table 53. Australia prevalence of Fabry disease by 5-yr age cohort, males (000s)
  • Table 54. Australia prevalence of Fabry disease by 5-yr age cohort, females (000s)
  • Table 55. Brazil prevalence of Fabry disease by 5-yr age cohort, males (000s)
  • Table 56. Brazil prevalence of Fabry disease by 5-yr age cohort, females (000s)
  • Table 57. Mexico prevalence of Fabry disease by 5-yr age cohort, males (000s)
  • Table 58. Mexico prevalence of Fabry disease by 5-yr age cohort, females (000s)
  • Table 59. Argentina prevalence of Fabry disease by 5-yr age cohort, males (000s)
  • Table 60. Argentina prevalence of Fabry disease by 5-yr age cohort, females (000s)
Back to Top
전화 문의
이용안내
 
BCC Research